TEL AVIV, Israel, June 10, 2026
Teva Pharmaceutical Industries Ltd. has completed its acquisition of Emalex Biosciences, strengthening its late-stage neuroscience pipeline with ecopipam, a first-in-class investigational therapy for pediatric Tourette syndrome (TS). The transaction represents a significant milestone in Teva’s “Pivot to Growth” strategy, expanding the company’s portfolio of innovative medicines while addressing a neurological disorder with substantial unmet medical need. Under the terms of the agreement, Teva paid $700 million upfront, with the potential for up to $200 million in additional commercial milestone payments, along with net sales-based royalties contingent on regulatory approval and commercialization. The acquisition provides Teva with a promising late-stage asset that could support both near-term and long-term revenue growth while reinforcing its strategic focus on neuroscience and specialty medicines.
Ecopipam Strengthens Teva’s Neuroscience Innovation Pipeline
The centerpiece of the acquisition is ecopipam, a novel investigational therapy designed to selectively block dopamine signaling through the D1 receptor, a mechanism believed to play a key role in the repetitive and compulsive behaviors associated with Tourette syndrome. Unlike currently available treatment options, ecopipam offers a differentiated approach by targeting dopamine D1 receptor activity rather than broader dopamine pathways. The therapy has already received FDA Orphan Drug Designation and Fast Track Designation, reflecting both its potential clinical importance and the urgent need for improved treatment options for pediatric patients.
Teva expects to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration during the second half of 2026, positioning the company for a potential regulatory milestone in the coming year. By adding a late-stage candidate with a novel mechanism of action, Teva continues to expand its innovative portfolio beyond its traditional generics business and strengthen its position as a leading biopharmaceutical company focused on high-value therapeutic areas.
Phase 3 Results Demonstrate Promise in Tourette Syndrome
Advertisement
Tourette syndrome is a chronic neurodevelopmental disorder characterized by involuntary motor and vocal tics that typically emerge during childhood and can significantly impact social, educational, and emotional well-being. Although existing therapies can help manage symptoms, many patients continue to experience inadequate control or treatment-limiting side effects. Ecopipam has generated encouraging clinical data in this underserved population. Results from the recently published Phase 3 study in JAMA Neurology demonstrated statistically significant efficacy compared with placebo in pediatric patients with Tourette syndrome.
The trial achieved its primary endpoint of time to relapse, showing a significant difference between ecopipam and placebo (p = 0.0084). The therapy was also generally well tolerated, with the most commonly reported adverse events including somnolence, insomnia, anxiety, fatigue, and headache. These findings support the potential of ecopipam to become an important new treatment option for children and adolescents living with Tourette syndrome while validating its differentiated scientific approach.
Acquisition Accelerates Teva’s Pivot to Growth Strategy
The acquisition highlights Teva’s commitment to accelerating innovation through targeted business development initiatives. Emalex Biosciences, originally established by Paragon Biosciences to develop therapies for central nervous system disorders, successfully advanced ecopipam through clinical development and prepared the NDA package for regulatory submission. By integrating this advanced-stage asset into its neuroscience portfolio, Teva gains an opportunity to address a rare neurological condition while expanding its presence in specialty pharmaceuticals. Company leadership emphasized that combining Teva’s extensive neuroscience expertise with ecopipam’s clinical potential creates a strong foundation for future growth.
As the pharmaceutical industry increasingly focuses on precision therapies targeting unmet medical needs, acquisitions involving late-stage assets with regulatory momentum continue to play a critical role in pipeline expansion. The completion of the Emalex transaction strengthens Teva’s innovation strategy, enhances its late-stage development portfolio, and positions the company to potentially deliver a new therapeutic option for pediatric Tourette syndrome patients worldwide.
Source: Teva, Emalex Biosciences press release
